Elston George 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Feb 11, 2025
Insider Transaction Report
Form 4
Elston George
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-09+5,834→ 75,550 total - Exercise/Conversion
Restricted Stock Units
2025-02-09−5,834→ 0 totalExercise: $0.00→ Common Stock (5,834 underlying)
Footnotes (2)
- [F1]Includes 1,150 shares acquired on January 31, 2025 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
- [F2]The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.